BCL2 and glioblastoma: Marizomib, a BBB-permeable proteasome inhibitor, has been shown to significantly affect LN229 and U118 GBM cell lines’ viability in a time/dose-dependent manner through caspase-3, NOXA, DR5, and cytochrome upregulation and Bcl-2 downregulation.